{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:39:48Z","timestamp":1792543188343,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"e Ningxia Natural Science Foundation Key Project","award":["2023AAC02061"],"award-info":[{"award-number":["2023AAC02061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the efficacy of dupilumab in treating moderate-to-severe atopic dermatitis (AD) in children aged 6 months to 6 years and to investigate the clinical characteristics influencing early super-responders\uff08eSR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study adopted a prospective design and enrolled pediatric patients with moderate-to-severe AD who were treated at the Department of Dermatology, General Hospital of Ningxia Medical University, from January 2023 to March 2025. In accordance with the patients\u2019 age and body weight, a subcutaneous injection of dupilumab (200\u2013300 mg) was administered every 4 weeks. At baseline, week 4, week 12, and week 16 of treatment, the efficacy of dupilumab and the family quality of life were evaluated using the following tools: the Eczema Area and Severity Index (EASI), Investigator\u2019s Global Assessment (IGA), Peak Pruritus Numeric Rating Scale (PP-NRS), Children\u2019s Dermatology Life Quality Index (CDLQI)\/Infant\u2019s Dermatology Life Quality Index (IDQoL), and Dermatitis Family Impact (DFI). Improvements in comorbid conditions were assessed using the Rhinoconjunctivitis Control Assessment Test (RCAT), Child Asthma Control Test (C-ACT), and Oral Food Challenge (OFC). Moreover, adverse events that occurred during the treatment period were recorded systematically. The proportions of patients who achieved EASI75 (\u226575% improvement in EASI score from baseline), a \u22654-point reduction in PP-NRS, and a \u22654-point improvement in CDLQI \/ IDQoL concurrently at week 4, as well as those who met both EASI75 and IGA 0\/1(clear\/almost clear) at week 16, were documented. Linear mixed models were used to analyze changes in clinical scores at different time points before and after dupilumab treatment, and logistic regression was applied to identify factors influencing eSR to dupilumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 50 children with moderate to severe AD, including 21 males (42.00%) and 29 females (58.00%), aged 4.24\u00b11.81, were included in this study. Clinical scores related to skin lesions and pruritus were significantly lower at weeks 4, 12, and 16 postdupilumab treatment than at baseline (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). At week 4, 40.00% (20\/50) of patients achieved the primary efficacy endpoints. By week 16, 87.10% (27\/31) and 90.32% (28\/31) of patients had EASI75 and an IGA 0\/1, respectively. The proportion of patients with severe\/moderate DFI scores decreased markedly from 100% at baseline to 9.68% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Notably, the prevalence of recurrent upper respiratory tract infections decreased significantly (P = 0.017), while the improvement rates for allergic rhinitis and food allergies reached 84.21% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and 84.61% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), respectively. Multivariate logistic regression revealed that a high absolute basophil count (OR = 0.104, 95% CI = 0.021-0.506,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005) and the\u00a0presence\u00a0of allergic rhinitis (OR = 0.223, 95% CI = 0.055-0.896,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.035) were independent predictors of eSR. Receiver operating characteristic (ROC) curve analysis demonstrated high predictive accuracy (AUC = 0.773;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001), indicating that a baseline absolute basophil count less than 0.035\u00d7109\/L was associated with a better eSR to dupilumab. No serious adverse events were observed during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab demonstrates significant efficacy and a favorable safety profile in the treatment of moderate-to-severe atopic dermatitis in children aged 6 months to 6 years. During treatment, patients presented alleviated allergic comorbidities, decreased incidence of recurrent upper respiratory tract infections, and improved quality of life for children and their families. Elevated absolute basophil count in peripheral blood and the\u00a0presence\u00a0of allergic rhinitis were independent predictors of eSR to dupilumab in children with AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-026-07381-6","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:55:11Z","timestamp":1784732111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders"],"prefix":"10.1186","volume":"26","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"7381_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190(1):55\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad339.","journal-title":"Br J Dermatol"},{"issue":"8","key":"7381_CR2","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/jdv.15618","volume":"33","author":"Y Guo","year":"2019","unstructured":"Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1\u201312 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence. J Eur Acad Dermatol Venereol. 2019;33(8):1569\u201376. https:\/\/doi.org\/10.1111\/jdv.15618.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"7381_CR3","doi-asserted-by":"publisher","first-page":"e15901","DOI":"10.1111\/dth.15901","volume":"35","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):e15901. https:\/\/doi.org\/10.1111\/dth.15901.","journal-title":"Dermatol Ther"},{"issue":"1","key":"7381_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/pde.15468","volume":"41","author":"TA Kouwenhoven","year":"2024","unstructured":"Kouwenhoven TA, van Muijen ME, van de Kerkhof PCM, de Jong EMGJ, Kamsteeg M, Seyger MMB. Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients. Pediatr Dermatol. 2024;41(1):34\u201340. https:\/\/doi.org\/10.1111\/pde.15468.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"7381_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3760\/cma.j.cn114798-20220915-00924","volume":"22","author":"Dermatology","year":"2023","unstructured":"Chinese Medical Association; Chinese Medical Association Publishing House, Dermatology, Branch V, Chinese Medical Association. Guidelines for Primary Care Diagnosis and Treatment of Atopic Dermatitis in Children (2023). Chin J Gen Practitioners. 2023;22(1):8\u201318. https:\/\/doi.org\/10.3760\/cma.j.cn114798-20220915-00924.","journal-title":"Chin J Gen Practitioners"},{"key":"7381_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-5945-12-11","volume":"12","author":"LB von Kobyletzki","year":"2012","unstructured":"von Kobyletzki LB, Bornehag CG, Hasselgren M, et al. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol. 2012;12:11. https:\/\/doi.org\/10.1186\/1471-5945-12-11.","journal-title":"BMC Dermatol"},{"key":"7381_CR7","doi-asserted-by":"publisher","unstructured":"Chinese Medical Doctor Association Dermatologists Branch; Dermatology and Venereology Branch, Chinese Medical Association; Dermatology Branch, China International Exchange and Promotive Association for Medical and Health Care; et al Expert Consensus on the Application and Management of Therapeutic Agents for Atopic Dermatitis (2024 Version). Chinese Journal of Dermatology et al et al. 2024;57(2):97\u2013108. https:\/\/doi.org\/10.35541\/cjd.20230358.","DOI":"10.35541\/cjd.20230358"},{"issue":"10356","key":"7381_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"12","key":"7381_CR9","doi-asserted-by":"publisher","first-page":"e896","DOI":"10.1111\/jdv.17541","volume":"35","author":"E Nettis","year":"2021","unstructured":"Nettis E, Ferrucci SM, Pellacani G, et al. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response. J Eur Acad Dermatol Venereol. 2021;35(12):e896\u20138. https:\/\/doi.org\/10.1111\/jdv.17541.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"7381_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","volume":"50","author":"JM Hanifin","year":"2004","unstructured":"Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)\/American Academy of Dermatology Association Administrative Regulations for Evidence-Based Clinical Practice Guidelines. J Am Acad Dermatol. 2004;50(3):391\u2013404. https:\/\/doi.org\/10.1016\/j.jaad.2003.08.003.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"7381_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.13683\/j.wph.2024.09.013","volume":"45","author":"T GAO","year":"2024","unstructured":"GAO T, WANG R. Research Progress on Severity and Efficacy Assessment Scales for Atopic Dermatitis. World Clin Drugs. 2024;45(9):972\u20139. https:\/\/doi.org\/10.13683\/j.wph.2024.09.013.","journal-title":"World Clin Drugs"},{"issue":"5","key":"7381_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/all.13362","volume":"73","author":"JP Liedtke","year":"2018","unstructured":"Liedtke JP, Mandl A, K\u00f6ther J, et al. RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients. Allergy. 2018;73(5):1101\u20139. https:\/\/doi.org\/10.1111\/all.13362.","journal-title":"Allergy"},{"issue":"5","key":"7381_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3760\/cma.j.cn101070-20250331-00223","volume":"40","author":"R Group","year":"2025","unstructured":"Pediatrics Specialized Committee, China Association for Medical Education; Asthma Collaboration Group, Group R, Branch P, et al Guidelines for Diagnosis, Prevention, and Management of Bronchial Asthma in Children (2025 Patient and Public Version).Chinese Medical Association; Pediatric Respiratory Medicine Working Committee, Respiratory Physicians Branch, Chinese Medical Doctor Association. Chin J Appl Clin Pediatr. 2025;40(5):324\u201333.https:\/\/doi.org\/10.3760\/cma.j.cn101070-20250331-00223.","journal-title":"Chin J Appl Clin Pediatr"},{"key":"7381_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3760\/cma.j.cn101070-20220313-00257","volume":"37","author":"W ZHOU","year":"2022","unstructured":"ZHOU W, ZHAO J, CHE H, et al. Evidence-Based Guideline for Food Allergy in Chinese Children. Chin J Practical Pediatr. 2022;37:572\u201383. https:\/\/doi.org\/10.3760\/cma.j.cn101070-20220313-00257.","journal-title":"Chin J Practical Pediatr"},{"issue":"1","key":"7381_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjd.12232","volume":"169","author":"SR Dodington","year":"2013","unstructured":"Dodington SR, Basra MK, Finlay AY, et al. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013;169(1):31\u201346. https:\/\/doi.org\/10.1111\/bjd.12232.","journal-title":"Br J Dermatol"},{"key":"7381_CR16","doi-asserted-by":"publisher","unstructured":"Jesenak M, Urbancikova I, Banovcin P. Respiratory Tract Infections and the Role of Biologically Active Polysaccharides in Their Management and Prevention. Nutrients. 2017;9(7). https:\/\/doi.org\/10.3390\/nu9070779.","DOI":"10.3390\/nu9070779"},{"issue":"3","key":"7381_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.19538\/j.ek2022030601","volume":"37","author":"Allergy Specialized Group","year":"2022","unstructured":"Allergy Specialized Group, Respiratory Group, Rheumatology and Immunology Specialized Group, Pediatrics Branch, Chinese Medical Doctor Association. Clinical Practice Pathway for Recurrent Respiratory Tract Infections in Children (2022 Version). Chin J Practical Pediatr. 2022;37(3):161\u20138. https:\/\/doi.org\/10.19538\/j.ek2022030601.","journal-title":"Chin J Practical Pediatr"},{"issue":"2","key":"7381_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2013","unstructured":"Su\u00e1rez-Fari\u00f1as M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361\u201370. https:\/\/doi.org\/10.1016\/j.jaci.2013.04.046.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"7381_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3760\/cma.j.cn112140-20250124-00074","volume":"63","author":"Subspecialty Group of Respiratory t","year":"2025","unstructured":"Subspecialty Group of Respiratory t S o P C M A. <>Editorial Board C J o P China Medicine Education Association Committee on P 2025 Guidelines for the diagnosis and optimal management of asthma in children (2025). Zhonghua Er Ke Za Zhi 63 4 324\u201337 https:\/\/doi.org\/10.3760\/cma.j.cn112140-20250124-00074.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"27","key":"7381_CR20","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.12114\/j.issn.1007-9572.2018.00.201","volume":"21","author":"Food and Drug Allergy Prevention Specialized Group, Allergy Disease Prevention and Control Specialized Committee, Chinese Preventive Medicine Association","year":"2018","unstructured":"Food and Drug Allergy Prevention Specialized Group, Allergy Disease Prevention and Control Specialized Committee, Chinese Preventive Medicine Association. Expert Consensus on Standardized Process of Oral Food Challenge. Chin J Gen Pract. 2018;21(27):3281\u20134. https:\/\/doi.org\/10.12114\/j.issn.1007-9572.2018.00.201.","journal-title":"Chin J Gen Pract"},{"issue":"3","key":"7381_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1399-3038.2006.00502.x","volume":"18","author":"G Ricci","year":"2007","unstructured":"Ricci G, Bendandi B, Bellini F, et al. Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score. Pediatr Allergy Immunol. 2007;18(3):245\u20139. https:\/\/doi.org\/10.1111\/j.1399-3038.2006.00502.x.","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"7381_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000535282","volume":"240","author":"E Berna-Rico","year":"2024","unstructured":"Berna-Rico E, Fiz-Benito E, Busto-Leis JM, et al. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024;240(2):337\u201342. https:\/\/doi.org\/10.1159\/000535282.","journal-title":"Dermatology"},{"issue":"1","key":"7381_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/pde.15418","volume":"41","author":"S Martinez-Cabriales","year":"2024","unstructured":"Martinez-Cabriales S, Marcoux D, Liy-Wong C, et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2024;41(1):5\u201311. https:\/\/doi.org\/10.1111\/pde.15418.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"7381_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3969\/j.issn.1673-8705.2024.03.017","volume":"18","author":"J LI","year":"2024","unstructured":"LI J, HE R, YANG S, et al. Case Report: Dupilumab Treatment for Atopic Dermatitis in Children Aged\u2009<\u20096 Years. Chin J Clin Immunol Allergy. 2024;18(3):296\u2013302. https:\/\/doi.org\/10.3969\/j.issn.1673-8705.2024.03.017.","journal-title":"Chin J Clin Immunol Allergy"},{"issue":"4","key":"7381_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2019.12.024","volume":"124","author":"LJ Meltzer","year":"2020","unstructured":"Meltzer LJ, Flewelling KD, Jump S, et al. Impact of atopic dermatitis treatment on child and parent sleep, daytime functioning, and quality of life. Ann Allergy Asthma Immunol. 2020;124(4):385\u201392. https:\/\/doi.org\/10.1016\/j.anai.2019.12.024.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"7381_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1089\/derm.2023.0362","volume":"35","author":"JCH Yap","year":"2024","unstructured":"Yap JCH, Yew YW. Impact of Atopic Dermatitis\u00ae on Quality of Life of Caregivers: A Systematic Review and Meta-Analysis. Dermatitis: contact atopic Occup drug. 2024;35(6):554\u201395. https:\/\/doi.org\/10.1089\/derm.2023.0362.","journal-title":"Dermatitis: contact atopic Occup drug"},{"issue":"4","key":"7381_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5415\/apallergy.2016.6.4.213","volume":"6","author":"HJ Jang","year":"2016","unstructured":"Jang HJ, Hwang S, Ahn Y, et al. Family quality of life among families of children with atopic dermatitis. Asia Pac allergy. 2016;6(4):213\u20139. https:\/\/doi.org\/10.5415\/apallergy.2016.6.4.213.","journal-title":"Asia Pac allergy"},{"issue":"1","key":"7381_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.23736\/S2784-8671.19.06447-2","volume":"156","author":"M Ra\u017enatovi\u0107 \u00d0urovi\u0107","year":"2021","unstructured":"Ra\u017enatovi\u0107 \u00d0urovi\u0107 M, Jankovi\u0107 J, \u0106irkovi\u0107 A, et al. Impact of atopic dermatitis on the quality of life of children and their families. Italian J dermatology Venereol. 2021;156(1):29\u201335. https:\/\/doi.org\/10.23736\/S2784-8671.19.06447-2.","journal-title":"Italian J dermatology Venereol"},{"issue":"1","key":"7381_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/bjd.19825","volume":"185","author":"C Droitcourt","year":"2021","unstructured":"Droitcourt C, Vittrup I, Dupuy A, et al. Risk of systemic infections requiring hospitalization in children with atopic dermatitis: a Danish retrospective nationwide cohort study. Br J Dermatol. 2021;185(1):119\u201329. https:\/\/doi.org\/10.1111\/bjd.19825.","journal-title":"Br J Dermatol"},{"issue":"10","key":"7381_CR30","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/all.16265","volume":"79","author":"SY Tsai","year":"2024","unstructured":"Tsai SY, Gaffin JM, Hawryluk EB, et al. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study. Allergy. 2024;79(10):2748\u201358. https:\/\/doi.org\/10.1111\/all.16265.","journal-title":"Allergy"},{"issue":"2","key":"7381_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","volume":"150","author":"KM Buchheit","year":"2022","unstructured":"Buchheit KM, Sohail A, Hacker J, et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2022;150(2):415\u201324. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"7381_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","volume":"143","author":"WF Davidson","year":"2019","unstructured":"Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on Atopic dermatitis and the atopic march: Mechanisms and interventions. J Allergy Clin Immunol. 2019;143(3):894\u2013913. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"7381_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.35541\/cjd.20201030","volume":"54","author":"L Liang Yunsheng","year":"2021","unstructured":"Liang Yunsheng L, Zhao. Type 2 inflammatory responses in atopic dermatitis. Chin J Dermatology. 2021;54(1):84\u20138. https:\/\/doi.org\/10.35541\/cjd.20201030.","journal-title":"Chin J Dermatology"},{"issue":"3","key":"7381_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","volume":"91","author":"TL Lin","year":"2024","unstructured":"Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. J Am Acad Dermatol. 2024;91(3):466\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.029.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"7381_CR35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.35541\/cjd.20240159","volume":"57","author":"C Wang Jiayi","year":"2024","unstructured":"Wang Jiayi C, Qiaozhi P, Cong L. Efficacy of dupilumab in the treatment of moderate to severe atopic dermatitis in children and analysis of its influencing factors. Chin J Dermatology. 2024;57(12):1099\u2013106. https:\/\/doi.org\/10.35541\/cjd.20240159.","journal-title":"Chin J Dermatology"},{"key":"7381_CR36","doi-asserted-by":"publisher","first-page":"1644875","DOI":"10.3389\/fimmu.2025.1644875","volume":"16","author":"Y Xu","year":"2025","unstructured":"Xu Y, Li B, Wang W. Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China. Front Immunol. 2025;16:1644875. https:\/\/doi.org\/10.3389\/fimmu.2025.1644875. Published 2025 Jul 17.","journal-title":"Front Immunol"},{"key":"7381_CR37","doi-asserted-by":"publisher","first-page":"1524962","DOI":"10.3389\/fped.2024.1524962","volume":"12","author":"Y Chen","year":"2025","unstructured":"Chen Y, Ni J, Li M, et al. Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study. Front Pediatr. 2025;12:1524962. https:\/\/doi.org\/10.3389\/fped.2024.1524962. Published 2025 Jan 17.","journal-title":"Front Pediatr"},{"key":"7381_CR38","doi-asserted-by":"publisher","first-page":"589513","DOI":"10.2147\/CCID.S589513","volume":"19","author":"S Ko\u00e7 Y\u0131ld\u0131r\u0131m","year":"2026","unstructured":"Ko\u00e7 Y\u0131ld\u0131r\u0131m S, Ayy\u0131ld\u0131z SM, Demirel \u00d6\u011f\u00fct N, et al. Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence. Clin Cosmet Investig Dermatol. 2026;19:589513. https:\/\/doi.org\/10.2147\/CCID.S589513.Published 2026 Mar 19.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"7381_CR39","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1111\/bjd.16543","volume":"178","author":"JR Chalmers","year":"2018","unstructured":"Chalmers JR, Thomas KS, Apfelbacher C, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema\/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2018;178(5):e332\u201341. https:\/\/doi.org\/10.1111\/bjd.16543.","journal-title":"Br J Dermatol"},{"key":"7381_CR40","doi-asserted-by":"publisher","unstructured":"Ferrucci S, Casazza G, Angileri L, et al. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience. J Clin Med. 2020;9(3). https:\/\/doi.org\/10.3390\/jcm9030791.","DOI":"10.3390\/jcm9030791"},{"key":"7381_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/JAA.S508697","volume":"18","author":"L Yu","year":"2025","unstructured":"Yu L, Lian C, Li L, et al. Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients. J Asthma Allergy. 2025;18:331\u20137. https:\/\/doi.org\/10.2147\/JAA.S508697. Published 2025 Mar 5.","journal-title":"J Asthma Allergy"},{"key":"7381_CR42","doi-asserted-by":"publisher","unstructured":"Hou T, Tsang MS, Kan LL et al. IL-37 Targets TSLP-Primed Basophils to Alleviate Atopic Dermatitis. Int J Mol Sci. 2021;22(14):7393. https:\/\/doi.org\/10.3390\/ijms22147393.Published 2021 Jul 9.","DOI":"10.3390\/ijms22147393"},{"issue":"6","key":"7381_CR43","doi-asserted-by":"publisher","first-page":"e23214","DOI":"10.1002\/jcla.23214","volume":"34","author":"Y Hu","year":"2020","unstructured":"Hu Y, Liu S, Liu P, et al. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal. 2020;34(6):e23214. https:\/\/doi.org\/10.1002\/jcla.23214.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"7381_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ni1558","volume":"9","author":"S CL","year":"2008","unstructured":"CL S, GM B, AG F, et al. A mechanism for the initiation of allergen-induced T helper type 2 responses[J]. Nat Immunol. 2008;9(3):310\u20138.","journal-title":"Nat Immunol"},{"issue":"3","key":"7381_CR45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Yokozeki H, Karasuyama H, et al. IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin[J]. J Allergy Clin Immunol. 2023;151(3):737\u2013e7466.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"7381_CR46","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.jid.2019.04.016","volume":"139","author":"Y Imai","year":"2019","unstructured":"Imai Y, Yasuda K, Nagai M, et al. IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils. J Invest Dermatol. 2019;139(10):2185\u2013e21943. https:\/\/doi.org\/10.1016\/j.jid.2019.04.016.","journal-title":"J Invest Dermatol"},{"key":"7381_CR47","doi-asserted-by":"publisher","first-page":"1213138","DOI":"10.3389\/fimmu.2023.1213138","volume":"14","author":"D Wiebe","year":"2023","unstructured":"Wiebe D, Limberg MM, Gray N, et al. Basophils in pruritic skin diseases. Front Immunol. 2023;14:1213138. https:\/\/doi.org\/10.3389\/fimmu.2023.1213138. Published 2023 Jul 3.","journal-title":"Front Immunol"},{"issue":"2","key":"7381_CR48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","volume":"184","author":"F Wang","year":"2021","unstructured":"Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch. Cell. 2021;184(2):422\u2013e44017. https:\/\/doi.org\/10.1016\/j.cell.2020.12.033.","journal-title":"Cell"},{"issue":"3","key":"7381_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000321222","volume":"81","author":"GH Dong","year":"2011","unstructured":"Dong GH, Ren WH, Wang D, et al. Exposure to secondhand tobacco smoke enhances respiratory symptoms and responses to animals in 8,819 children in kindergarten: results from 25 districts in northeast China. Respiration. 2011;81(3):179\u201385. https:\/\/doi.org\/10.1159\/000321222.","journal-title":"Respiration"},{"issue":"1","key":"7381_CR50","first-page":"73","volume":"29","author":"S Siriaksorn","year":"2011","unstructured":"Siriaksorn S, Suchaitanawanit S, Trakultivakorn M. Allergic rhinitis and immunoglobulin deficiency in preschool children with frequent upper respiratory illness. Asian Pac J Allergy Immunol. 2011;29(1):73\u20137.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"4","key":"7381_CR51","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/all.15108","volume":"77","author":"AM Schoos","year":"2022","unstructured":"Schoos AM, Chawes BL, B\u00f8nnelykke K, et al. Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood. Allergy. 2022;77(4):1254\u201362. https:\/\/doi.org\/10.1111\/all.15108.","journal-title":"Allergy"},{"issue":"11","key":"7381_CR52","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.35541\/cjd.20230099","volume":"57","author":"X Xie","year":"2024","unstructured":"Xie X, Zhang L, Du D, et al. Advances in the comorbidities of atopic dermatitis. Chin J Dermatology. 2024;57(11):1058\u201363. https:\/\/doi.org\/10.35541\/cjd.20230099.","journal-title":"Chin J Dermatology"},{"issue":"11","key":"7381_CR53","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1016\/j.jaip.2024.08.054","volume":"12","author":"P Chokevittaya","year":"2024","unstructured":"Chokevittaya P, Jirattikanwong N, Thongngarm T, et al. Factors Associated With Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2024;12(11):3044\u201356. https:\/\/doi.org\/10.1016\/j.jaip.2024.08.054.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7381_CR54","doi-asserted-by":"publisher","first-page":"1160710","DOI":"10.3389\/fimmu.2023.1160710","volume":"14","author":"A Wang","year":"2023","unstructured":"Wang A, Zhou Y, Luo Y, et al. High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https:\/\/doi.org\/10.3389\/fimmu.2023.1160710.","journal-title":"Front Immunol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07381-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07381-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07381-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:18:06Z","timestamp":1792541886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07381-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7381"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07381-6","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"7 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by the Ethics Committee of the General Hospital of Ningxia Medical University. The studies were conducted in accordance with local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants\u2019 legal guardians\/next of kin.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1028"}}